stopwords, and 2-character and smaller words are excluded
TICAM-1, an adaptor molecule that participates in Toll-like
receptor 3-mediated interferon-beta induction
Oshiumi H, Matsumoto M, Funami K, Akazawa T, Seya T
NATURE IMMUNOLOGY 4 (2): 161-167 FEB 2003
and the citing papers
Total: 668, Nodes: 194, Word count: 1792, All words count: 2511
View: Overview. Sorted by number of publications (Pubs).
Page 2 of 4: [ 1 2 3 4 ]
| # | Word | Pubs | Percent | TLCS | TGCS
|
|---|
| 201 | PROFILING | 2 | 1.0 | 0 | 10
|
| 202 | PROGRAM | 2 | 1.0 | 2 | 16
|
| 203 | PROINFLAMMATORY | 2 | 1.0 | 1 | 13
|
| 204 | PROPERTIES | 2 | 1.0 | 0 | 10
|
| 205 | REGULATE | 2 | 1.0 | 1 | 9
|
| 206 | REGULATES | 2 | 1.0 | 0 | 2
|
| 207 | RESPIRATORY | 2 | 1.0 | 1 | 24
|
| 208 | RNAS | 2 | 1.0 | 3 | 22
|
| 209 | ROAD | 2 | 1.0 | 0 | 20
|
| 210 | SENSING | 2 | 1.0 | 4 | 16
|
| 211 | SEPSIS | 2 | 1.0 | 1 | 6
|
| 212 | SEQUENCE-INDEPENDENT | 2 | 1.0 | 2 | 25
|
| 213 | SHIP | 2 | 1.0 | 0 | 28
|
| 214 | SPECIFICITY | 2 | 1.0 | 13 | 46
|
| 215 | SUBCELLULAR | 2 | 1.0 | 20 | 59
|
| 216 | SUPPRESSION | 2 | 1.0 | 2 | 25
|
| 217 | SYNCYTIAL | 2 | 1.0 | 1 | 24
|
| 218 | TANK-BINDING | 2 | 1.0 | 38 | 69
|
| 219 | TARGET | 2 | 1.0 | 4 | 12
|
| 220 | THERAPEUTIC | 2 | 1.0 | 1 | 15
|
| 221 | TNF | 2 | 1.0 | 31 | 55
|
| 222 | TRIF-INDUCED | 2 | 1.0 | 3 | 6
|
| 223 | TWO | 2 | 1.0 | 41 | 73
|
| 224 | TYROSINE | 2 | 1.0 | 3 | 10
|
| 225 | UP-REGULATION | 2 | 1.0 | 6 | 11
|
| 226 | ZEBRAFISH | 2 | 1.0 | 3 | 19
|
| 227 | A46R | 1 | 0.5 | 0 | 1
|
| 228 | ABSENCE | 1 | 0.5 | 0 | 3
|
| 229 | ACID-MEDIATED | 1 | 0.5 | 0 | 3
|
| 230 | ACQUIRED | 1 | 0.5 | 0 | 1
|
| # | Word | Pubs | Percent | TLCS | TGCS
|
|---|
| 231 | ACTION | 1 | 0.5 | 0 | 0
|
| 232 | ACTIVATE | 1 | 0.5 | 1 | 3
|
| 233 | ACTIVATED | 1 | 0.5 | 2 | 12
|
| 234 | ACTIVITIES | 1 | 0.5 | 0 | 10
|
| 235 | ACTIVITY | 1 | 0.5 | 0 | 0
|
| 236 | ACUTE | 1 | 0.5 | 0 | 12
|
| 237 | ADAPTOR-INDUCING | 1 | 0.5 | 2 | 4
|
| 238 | ADJUVANCY | 1 | 0.5 | 0 | 1
|
| 239 | ADJUVANT | 1 | 0.5 | 2 | 12
|
| 240 | ADJUVANT-MEDIATED | 1 | 0.5 | 2 | 2
|
| 241 | AFFERENT | 1 | 0.5 | 1 | 3
|
| 242 | AIRWAY | 1 | 0.5 | 0 | 1
|
| 243 | AKT | 1 | 0.5 | 3 | 17
|
| 244 | ALLERGIC | 1 | 0.5 | 0 | 0
|
| 245 | ALLOGRAFTS | 1 | 0.5 | 0 | 3
|
| 246 | ALLOIMMUNITY | 1 | 0.5 | 0 | 1
|
| 247 | ALTERNATE | 1 | 0.5 | 0 | 0
|
| 248 | ALTERNATIVE | 1 | 0.5 | 0 | 0
|
| 249 | ANIMAL | 1 | 0.5 | 0 | 0
|
| 250 | ANTAGONISTS | 1 | 0.5 | 0 | 4
|
| 251 | ANTI-INFLAMMATORY | 1 | 0.5 | 0 | 1
|
| 252 | ANTICIPATED | 1 | 0.5 | 0 | 0
|
| 253 | ANTIFUNGAL | 1 | 0.5 | 0 | 0
|
| 254 | AP-1-DEPENDENT | 1 | 0.5 | 5 | 9
|
| 255 | APC-INDEPENDENT | 1 | 0.5 | 4 | 15
|
| 256 | APOPTOTIC | 1 | 0.5 | 1 | 2
|
| 257 | APPROACH | 1 | 0.5 | 0 | 9
|
| 258 | APPROACHES | 1 | 0.5 | 0 | 0
|
| 259 | APPROPRIATION | 1 | 0.5 | 1 | 2
|
| 260 | ARTHRITIS | 1 | 0.5 | 1 | 15
|
| # | Word | Pubs | Percent | TLCS | TGCS
|
|---|
| 261 | ARTHRITOGENIC | 1 | 0.5 | 0 | 1
|
| 262 | ASSAY | 1 | 0.5 | 0 | 10
|
| 263 | ASSESSMENT | 1 | 0.5 | 0 | 10
|
| 264 | ASSOCIATED | 1 | 0.5 | 0 | 0
|
| 265 | ASSOCIATES | 1 | 0.5 | 31 | 53
|
| 266 | ASSOCIATION | 1 | 0.5 | 0 | 8
|
| 267 | ATTRACTION | 1 | 0.5 | 0 | 0
|
| 268 | AUTOIMMUNE | 1 | 0.5 | 0 | 0
|
| 269 | AUTOPHOSPHORYLATION | 1 | 0.5 | 0 | 6
|
| 270 | AUTOREGULATORY | 1 | 0.5 | 0 | 0
|
| 271 | AVAILABILITY | 1 | 0.5 | 0 | 6
|
| 272 | B-ACTIVATING | 1 | 0.5 | 0 | 1
|
| 273 | B-AND | 1 | 0.5 | 5 | 9
|
| 274 | BACILLUS | 1 | 0.5 | 8 | 14
|
| 275 | BACTERIA | 1 | 0.5 | 1 | 2
|
| 276 | BACTERIA-INFECTED | 1 | 0.5 | 0 | 5
|
| 277 | BASED | 1 | 0.5 | 0 | 2
|
| 278 | BETA-STAT | 1 | 0.5 | 0 | 4
|
| 279 | BIOINFORMATICS | 1 | 0.5 | 0 | 0
|
| 280 | BIOLOGICAL | 1 | 0.5 | 7 | 23
|
| 281 | BIOLOGY | 1 | 0.5 | 0 | 3
|
| 282 | BLOCK | 1 | 0.5 | 1 | 24
|
| 283 | BLOCKING | 1 | 0.5 | 8 | 14
|
| 284 | BOVINE | 1 | 0.5 | 1 | 24
|
| 285 | BRIDGE | 1 | 0.5 | 1 | 6
|
| 286 | BRIDGING | 1 | 0.5 | 38 | 51
|
| 287 | BRUTON | 1 | 0.5 | 0 | 4
|
| 288 | BTK | 1 | 0.5 | 0 | 4
|
| 289 | C-JUN | 1 | 0.5 | 1 | 1
|
| 290 | CALMETTE-GUERIN | 1 | 0.5 | 8 | 14
|
| # | Word | Pubs | Percent | TLCS | TGCS
|
|---|
| 291 | CANCER | 1 | 0.5 | 2 | 12
|
| 292 | CARDIAC | 1 | 0.5 | 0 | 4
|
| 293 | CASCADES | 1 | 0.5 | 1 | 3
|
| 294 | CATIONIC | 1 | 0.5 | 0 | 0
|
| 295 | CD11C | 1 | 0.5 | 0 | 3
|
| 296 | CDNA | 1 | 0.5 | 2 | 5
|
| 297 | CELL-DERIVED | 1 | 0.5 | 0 | 3
|
| 298 | CELL-WALL | 1 | 0.5 | 0 | 1
|
| 299 | CELLULAR | 1 | 0.5 | 0 | 0
|
| 300 | CENTER | 1 | 0.5 | 19 | 43
|
| 301 | CHEMOKINE | 1 | 0.5 | 0 | 0
|
| 302 | CHEMOKINES | 1 | 0.5 | 1 | 1
|
| 303 | CHIMERIC | 1 | 0.5 | 0 | 9
|
| 304 | CHRONIC | 1 | 0.5 | 0 | 2
|
| 305 | CLEAVAGE | 1 | 0.5 | 2 | 5
|
| 306 | CLOSER | 1 | 0.5 | 0 | 0
|
| 307 | CONFERS | 1 | 0.5 | 0 | 0
|
| 308 | CONSERVED | 1 | 0.5 | 2 | 8
|
| 309 | CONTAINING | 1 | 0.5 | 0 | 0
|
| 310 | CONTRIBUTES | 1 | 0.5 | 0 | 1
|
| 311 | CONTROLLING | 1 | 0.5 | 0 | 13
|
| 312 | CORNEAL | 1 | 0.5 | 0 | 0
|
| 313 | COUNTERACT | 1 | 0.5 | 0 | 0
|
| 314 | CRUZI | 1 | 0.5 | 0 | 12
|
| 315 | CULTURE | 1 | 0.5 | 0 | 0
|
| 316 | CWS | 1 | 0.5 | 0 | 1
|
| 317 | CYCLOOXYGENASE | 1 | 0.5 | 0 | 7
|
| 318 | CYTOPLASMIC | 1 | 0.5 | 1 | 5
|
| 319 | CYTOTOXICITY | 1 | 0.5 | 0 | 2
|
| 320 | DANGER | 1 | 0.5 | 0 | 4
|
| # | Word | Pubs | Percent | TLCS | TGCS
|
|---|
| 321 | DANIO | 1 | 0.5 | 0 | 0
|
| 322 | DC-VIRUS | 1 | 0.5 | 0 | 3
|
| 323 | DEACTIVATION | 1 | 0.5 | 0 | 10
|
| 324 | DEATH | 1 | 0.5 | 0 | 4
|
| 325 | DEFECTIVE | 1 | 0.5 | 21 | 40
|
| 326 | DEFENCE | 1 | 0.5 | 0 | 0
|
| 327 | DEFENSE | 1 | 0.5 | 0 | 0
|
| 328 | DEFICIENCY | 1 | 0.5 | 11 | 89
|
| 329 | DEFINE | 1 | 0.5 | 5 | 29
|
| 330 | DEFINED | 1 | 0.5 | 0 | 10
|
| 331 | DELTA | 1 | 0.5 | 0 | 3
|
| 332 | DENDRITIC-CELL | 1 | 0.5 | 2 | 62
|
| 333 | DERIVATIVES | 1 | 0.5 | 0 | 0
|
| 334 | DETECT | 1 | 0.5 | 4 | 57
|
| 335 | DETERMINANTS | 1 | 0.5 | 0 | 0
|
| 336 | DETERMINES | 1 | 0.5 | 4 | 11
|
| 337 | DIMERIZED | 1 | 0.5 | 1 | 9
|
| 338 | DIMINISHED | 1 | 0.5 | 0 | 3
|
| 339 | DIPEPTIDE | 1 | 0.5 | 0 | 0
|
| 340 | DIRECT | 1 | 0.5 | 4 | 23
|
| 341 | DIRECTLY | 1 | 0.5 | 2 | 12
|
| 342 | DISEASES | 1 | 0.5 | 1 | 13
|
| 343 | DISORDERS | 1 | 0.5 | 0 | 1
|
| 344 | DISPLAY | 1 | 0.5 | 2 | 5
|
| 345 | DISSECTION | 1 | 0.5 | 1 | 3
|
| 346 | DISTINCTIVE | 1 | 0.5 | 0 | 9
|
| 347 | DNA | 1 | 0.5 | 0 | 7
|
| 348 | DOT | 1 | 0.5 | 19 | 43
|
| 349 | EBOLA | 1 | 0.5 | 3 | 28
|
| 350 | EDGED | 1 | 0.5 | 0 | 3
|
| # | Word | Pubs | Percent | TLCS | TGCS
|
|---|
| 351 | EFFECTS | 1 | 0.5 | 0 | 1
|
| 352 | ELICITS | 1 | 0.5 | 0 | 1
|
| 353 | EMBRYONIC | 1 | 0.5 | 21 | 40
|
| 354 | EMERGING | 1 | 0.5 | 0 | 2
|
| 355 | EMPLOYING | 1 | 0.5 | 19 | 43
|
| 356 | ENCODED | 1 | 0.5 | 0 | 1
|
| 357 | ENDOGENOUS | 1 | 0.5 | 5 | 25
|
| 358 | ENDOTHELIAL | 1 | 0.5 | 0 | 4
|
| 359 | ENDOTOXINS | 1 | 0.5 | 0 | 0
|
| 360 | EVASION | 1 | 0.5 | 2 | 5
|
| 361 | EVITHELIAL | 1 | 0.5 | 1 | 2
|
| 362 | EVOLUTION | 1 | 0.5 | 0 | 0
|
| 363 | EXOGENOUS | 1 | 0.5 | 0 | 6
|
| 364 | EXPANDING | 1 | 0.5 | 2 | 8
|
| 365 | EXPRESS | 1 | 0.5 | 0 | 0
|
| 366 | EXPRESSED | 1 | 0.5 | 2 | 5
|
| 367 | EXTRINSIC | 1 | 0.5 | 0 | 4
|
| 368 | FACTOR-3-MEDIATED | 1 | 0.5 | 4 | 7
|
| 369 | FADD-DEPENDENT | 1 | 0.5 | 1 | 7
|
| 370 | FAMILIES | 1 | 0.5 | 3 | 19
|
| 371 | FEMALE | 1 | 0.5 | 0 | 3
|
| 372 | FIBROBLASTS | 1 | 0.5 | 21 | 40
|
| 373 | FIVE | 1 | 0.5 | 0 | 2
|
| 374 | FORMATION | 1 | 0.5 | 0 | 8
|
| 375 | FULL-LENGTH | 1 | 0.5 | 0 | 0
|
| 376 | FULL-SCALE | 1 | 0.5 | 2 | 19
|
| 377 | FULLY | 1 | 0.5 | 0 | 3
|
| 378 | GAMMA | 1 | 0.5 | 0 | 3
|
| 379 | GENE-INDUCING | 1 | 0.5 | 0 | 1
|
| 380 | GENERATED | 1 | 0.5 | 0 | 0
|
| # | Word | Pubs | Percent | TLCS | TGCS
|
|---|
| 381 | GLUCOCORTICOIDS | 1 | 0.5 | 0 | 1
|
| 382 | GLYCAN | 1 | 0.5 | 2 | 18
|
| 383 | GROWS | 1 | 0.5 | 0 | 2
|
| 384 | HASHIMOTO | 1 | 0.5 | 0 | 0
|
| 385 | HAT | 1 | 0.5 | 0 | 2
|
| 386 | HCVNS | 1 | 0.5 | 0 | 0
|
| 387 | HEAT | 1 | 0.5 | 0 | 1
|
| 388 | HELICASE | 1 | 0.5 | 11 | 46
|
| 389 | HEPATOCYTES | 1 | 0.5 | 0 | 0
|
| 390 | HERPES | 1 | 0.5 | 16 | 95
|
| 391 | HETEROGENEITY | 1 | 0.5 | 0 | 1
|
| 392 | HETEROGENEOUS | 1 | 0.5 | 1 | 15
|
| 393 | HOMOLOGY | 1 | 0.5 | 0 | 1
|
| 394 | HOMOTYPIC | 1 | 0.5 | 0 | 0
|
| 395 | HUMANS | 1 | 0.5 | 11 | 89
|
| 396 | I-C | 1 | 0.5 | 0 | 0
|
| 397 | I-KAPPA | 1 | 0.5 | 3 | 7
|
| 398 | IDENTIFIED | 1 | 0.5 | 2 | 5
|
| 399 | IFN-GAMMA | 1 | 0.5 | 0 | 4
|
| 400 | IKK-EPSILON | 1 | 0.5 | 0 | 1
|
Page 2 of 4: [ 1 2 3 4 ]